N-Methylen<(p-tolyl)methyl>amin | 92667-48-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Methylen<(p-tolyl)methyl>amin
• 英文别名: N-[(4-methylphenyl)methyl]methanimine
• CAS: 92667-48-6
• 化学式: C₉H₁₁N
• 分子量: 133.193
• InChiKey: WVPBLBVOKVEATJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  silver(I) acetate 、 N-Methylen<(p-tolyl)methyl>amin 在 亚硝酰氯 作用下， 生成 N-Acetoxymethyl-N-nitroso<(p-tolyl)methyl>amin
  参考文献：
  名称：

  Mueller, Eduard; Kettler, Regina; Wiessler, Manfred, Liebigs Annalen der Chemie, 1984, # 8, p. 1468 - 1493

  摘要：

  DOI：
• 作为产物：
  描述：

  聚合甲醛 、 4-甲基苄胺 以83%的产率得到N-Methylen<(p-tolyl)methyl>amin
  参考文献：
  名称：

  Mueller, Eduard; Kettler, Regina; Wiessler, Manfred, Liebigs Annalen der Chemie, 1984, # 8, p. 1468 - 1493

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY<br/>[FR] INHIBITEURS DE L'HOMOLOGUE DE SPINSTER 2 (SPNS2) À UTILISER EN THÉRAPIE
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2022056042A1

  公开（公告）日：2022-03-17

  The present disclosure provides SPNS2 inhibitor compounds according to Formula (I) and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.

  本公开提供了符合公式（I）的SPNS2抑制剂化合物及其药学上可接受的盐和/或互变异构体，如本公开所述，并提供了它们的药物组合物和在治疗方面使用的方法。
• Tripeptide prodrug compounds
  申请人：Bebbington R. Christopher

  公开号：US20070275903A1

  公开（公告）日：2007-11-29

  The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.

  本发明的前药是治疗剂的改性形式，包括治疗剂、三个氨基酸的寡肽、稳定基和可选的连接基团。该前药可被Thimet寡肽酶等蛋白酶酶水解。本发明还公开了制备和使用前药化合物的方法。
• METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF
  申请人：Minowa Nobuto

  公开号：US20090270647A1

  公开（公告）日：2009-10-29

  A method for efficiently producing L-2-amino-4-(hydroxymethylphosphinyl)-butanoic acid, useful as a herbicide, by a catalytic asymmetric synthesis reaction with a high asymmetric yield. The method includes a step in which a compound represented by the below formula (1) and a benzylamine are reacted in the presence of dehydrating agent, then the resulting mass is reacted with hydrogen cyanide in the presence of an asymmetric catalyst, followed by acid hydrolysis, further followed by elimination of a protective group. [chemical formula 1] (1) (where, R 1 represents a C 1-4 alkyl group.)

  一种高效生产L-2-氨基-4-(羟甲基膦基)-丁酸，用作除草剂的方法，通过具有高不对称产率的催化不对称合成反应。该方法包括以下步骤：在脱水剂存在下，将化合物(1)和苄基胺反应，然后在不对称催化剂存在下将所得物质与氢氰酸反应，随后进行酸水解，进一步进行保护基的消除。[化学式1] (1) （其中，R1表示C1-4烷基。）
• Enzyme-cleavable prodrug compounds
  申请人：Dubois Vincent

  公开号：US20090110753A1

  公开（公告）日：2009-04-30

  The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.

  该发明的前药是治疗剂的改良形式，包括治疗剂、寡肽、稳定基团和可选的连接基团。该前药可被酶Thimet oligopeptidase（TOP）水解。还公开了利用共轭物中可被TOP水解的序列设计前药的方法以及利用该发明的前药治疗患者的方法。
• Pyrazole Derivatives
  申请人：Jones Lyn Howard

  公开号：US20120029192A1

  公开（公告）日：2012-02-02

  This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

  本发明涉及式（I）的吡唑衍生物或其药学上可接受的盐，溶剂或衍生物，以及其制备方法，用于制备中间体的组合物和这些衍生物的用途。本发明的化合物结合酶逆转录酶并且是调节剂，特别是抑制剂。因此，本发明的化合物在治疗包括逆转录酶抑制剂在内的多种疾病方面是有用的。感兴趣的疾病包括由人类免疫缺陷病毒（HIV）和遗传相关逆转录病毒引起的疾病，例如获得性免疫缺陷综合症（AIDS）。